ADITXT INC (ADTX) Stock News

Unusual volume stocks in Wednesday's session

The trading volume of these stocks is deviating from the norm in today's session.

Mentions: CYN MBIO OTRK LIXT ...

Which stocks have an unusual volume on Thursday?

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Mentions: SQNS ADIL PSTV VOR ...

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

Mentions: AEMD XTLB ICU ADIL ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Mentions: PSTV ANVS VYNE QS ...

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for...

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Why Aditxt Inc. (ADTX) Went Down On Thursday?

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Aditxt Inc. (NASDAQ:ADTX) stands against other stocks that fall behind amid market optimism. Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the […]

Mentions: TSLA

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended...

Mentions: EVFM

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Why Aditxt (ADTX) Stock Is Skyrocketing

Aditxt shares are trading higher by 65.6% during Tuesday's session. The company announced it submitted an application for four new federal funding opportunities.